Part 5/9:
When Visibly launched its services, initial resistance came primarily from the American Optometric Association, which viewed remote eye tests as a threat to traditional practices. In 2019, the FDA requested the company to pause sales temporarily, reflecting concerns about safety and efficacy. The FDA’s role is crucial—to prevent unqualified providers from offering substandard care—yet this regulatory environment also poses obstacles to technological progress.